Effect of low doses of clozapine on behaviour of isolated and group-housed male mice in the elevated plus-maze test

被引:29
作者
Manzaneque, JM
Brain, PF
Navarro, JF
机构
[1] Univ Malaga, Dept Psicobiol & Metodol, Fac Psicol, E-29071 Malaga, Spain
[2] Univ Coll Swansea, Sch Biol Sci, Swansea SA2 8PP, W Glam, Wales
关键词
anxiogenic; anxiolytic; clozapine; elevated plus-maze; isolation; neuroleptics;
D O I
10.1016/S0278-5846(01)00280-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clozapine is effective over a low and narrow dose range in the treatment of the negative symptoms of schizophrenia. Its efficacy is said to reflect an anxiolytic property of the neuroleptic. This study examined the effects of a low dose range of clozapine (0.1, 0.2 and 0.4 mg/kg) administered to isolated (7 days) and group-housed male mice on their behaviour in the elevated plus-maze. The results using this model of anxiety showed no dose-dependent effect on behaviour after treatment with low doses of clozapine. Some doses (0.1 and 0.4 mg/kg), however, reduced the duration and frequency of open arm entries compared to control-treated mice in the group-housed animals, This might indicate a slight anxiogenic effect. Support for this view is provided by some of the ethological measures, particularly head-dipping (HID). Seven days of isolation did not alter the main anxiety indices in controls. Nevertheless, some measures (e.g. closed entries and duration in the closed ann) were modified by the clozapine treatment (0.2 mg/kg) in a manner suggesting a mild anxiogenic action. The effects of the drug in individually and group-housed male mice were certainly different. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:349 / 355
页数:7
相关论文
共 54 条
[1]  
ALAMO C, 1996, NUEVOS ANTIPSICOTICO, P1
[2]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[3]   OLANZAPINE, AN ATYPICAL ANTIPSYCHOTIC, INCREASES RATES OF PUNISHED RESPONDING IN PIGEONS [J].
BENVENGA, MJ ;
LEANDER, JD .
PSYCHOPHARMACOLOGY, 1995, 119 (02) :133-138
[4]   Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbito-frontal cortex:: an in vivo electrophysiological study [J].
Bergqvist, PBF ;
Dong, JM ;
Blier, P .
PSYCHOPHARMACOLOGY, 1999, 143 (01) :89-96
[5]   DIAZEPAM CHANGES RISK ASSESSMENT IN AN ANXIETY DEFENSE TEST BATTERY [J].
BLANCHARD, DC ;
BLANCHARD, RJ ;
TOM, P ;
RODGERS, RJ .
PSYCHOPHARMACOLOGY, 1990, 101 (04) :511-518
[6]   ANXIOLYTIC POTENTIAL OF SULPIRIDE, CLOZAPINE AND DERIVATIVES IN THE OPEN-FIELD TEST [J].
BRUHWYLER, J ;
CHLEIDE, E ;
LIEGEOIS, JF ;
DELARGE, J ;
MERCIER, M .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1990, 36 (01) :57-61
[7]   Dopamine D-4 receptor and anxiety: Behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze [J].
Cao, BJ ;
Rodgers, RJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 335 (2-3) :117-125
[8]   ETHOLOGICAL EVALUATION OF THE EFFECTS OF ACUTE AND CHRONIC BUSPIRONE TREATMENT IN THE MURINE ELEVATED PLUS-MAZE TEST - COMPARISON WITH HALOPERIDOL [J].
COLE, JC ;
RODGERS, RJ .
PSYCHOPHARMACOLOGY, 1994, 114 (02) :288-296
[9]  
CORBETT R, 1993, PHARM BIOCH BEHAV, V45, P17
[10]   PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT1A agonist actions.: II.: Preclinical behavioral effects [J].
Corbin, AE ;
Meltzer, LT ;
Ninteman, FW ;
Wiley, JN ;
Cristoffersen, CL ;
Wustrow, DJ ;
Wise, LD ;
Pugsley, TA ;
Heffner, TG .
NEUROPHARMACOLOGY, 2000, 39 (07) :1211-1221